Ibrahim Aljuffali
Affiliations: | 2006-2010 | Pharmaceutical and Biomedical Sciences | University of Georgia, Athens, Athens, GA, United States |
Google:
"Ibrahim Aljuffali"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Robert D. Arnold | grad student | 2006-2010 | University of Georgia | |
| (? Dissertation Title: Use of nanoparticulate drug-carriers, dosing alteration, pharmacokinetic and pharmacodynamic modeling to optimize therapy) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Binkhathlan Z, Yusuf O, Ali R, et al. (2024) Polycaprolactone - Vitamin E TPGS micelles for delivery of paclitaxel: In vitro and in vivo evaluation. International Journal of Pharmaceutics: X. 7: 100253 |
| Aljuffali IA, Anwer MK, Ahmed MM, et al. (2023) Development of Gefitinib-Loaded Solid Lipid Nanoparticles for the Treatment of Breast Cancer: Physicochemical Evaluation, Stability, and Anticancer Activity in Breast Cancer (MCF-7) Cells. Pharmaceuticals (Basel, Switzerland). 16 |
| Anwer MK, Ahmed MM, Aldawsari MF, et al. (2023) Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box-Behnken Design, and Anti-Diarrheal Activity. Pharmaceutics. 15 |
| Aljuffali IA, Fang CL, Chen CH, et al. (2016) Nanomedicine as a strategy for natural compound delivery to prevent and treat cancers. Current Pharmaceutical Design |
| Kang JY, Eggert M, Mouli S, et al. (2015) Pharmacokinetics, antitumor and cardioprotective effects of liposome-encapsulated phenylaminoethyl selenide in human prostate cancer rodent models. Pharmaceutical Research. 32: 852-62 |
| Aljuffali IA, Brainard BM, Moore JN, et al. (2012) Pharmacokinetic assessment of ketanserin in the horse. Journal of Veterinary Pharmacology and Therapeutics. 35: 472-7 |
| Aljuffali IA, Mock JN, Costyn LJ, et al. (2011) Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. Cancer Biology & Therapy. 12: 407-20 |
| Zhu G, Mock JN, Aljuffali I, et al. (2011) Secretory phospholipase A 2 responsive liposomes Journal of Pharmaceutical Sciences. 100: 3146-3159 |
| Aljuffali I, Brainard B, Moore J, et al. (2010) Pharmacokinetics and Pharmacodynamics of Ketanserin Journal of Equine Veterinary Science. 30: 103-104 |